As of late April, the MyRealWorld™ MG (MRW MG) study has reached over 2,000 participants!
Study participants are based in Italy, the USA, Spain, Belgium, Canada, Japan, Germany, the UK, France, and Denmark. We would like to sincerely thank all participants, patient advocacy group representatives, and clinical experts who have made this achievement possible.
About MyRealWorld MG™
MRW MG is sponsored by argenx. This international observational longitudinal study has been designed with patients and clinical experts to understand the real-world impact of living with myasthenia gravis (MG). Visit our dedicated study page to find out more, or click here if you are a researcher who is interested in accessing the MRW MG dataset to gain insight into MG and improve patient care.
We are innovators in real-world evidence research. We connect biopharma to patients and caregivers on any device, worldwide – harnessing our scientific expertise and cutting-edge digital technology to generate real-time, real-world insights through the powerful combination of our Vitaccess Real™ digital platform and expert consultative insight.
Born in Oxford, we have team presence across Europe and the US. We are experts in health economics, patient-centered outcomes, analytics, software development, and localization, all committed to insightful digital research. We are passionate about inclusivity and open ways of working – we believe the more voices and views we listen to, the better we can make real progress, together.